224 related articles for article (PubMed ID: 31412345)
21. Serum ostase in the follow-up of breast cancer patients.
Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
[TBL] [Abstract][Full Text] [Related]
22. Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer.
Hung MJ; Oremek GM
Eur J Gynaecol Oncol; 2011; 32(6):615-8. PubMed ID: 22335021
[TBL] [Abstract][Full Text] [Related]
23. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
24. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
[TBL] [Abstract][Full Text] [Related]
25. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
26. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
[TBL] [Abstract][Full Text] [Related]
27. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R
Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845
[TBL] [Abstract][Full Text] [Related]
29. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
30. Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Begović S; Dzubur-Aganović M
Bosn J Basic Med Sci; 2005 Feb; 5(1):23-6. PubMed ID: 15771599
[TBL] [Abstract][Full Text] [Related]
31. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
32. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
33. New and traditional serum markers of bone metabolism in the detection of skeletal metastases.
Plebani M; Bernardi D; Zaninotto M; De Paoli M; Secchiero S; Sciacovelli L
Clin Biochem; 1996 Feb; 29(1):67-72. PubMed ID: 8929827
[TBL] [Abstract][Full Text] [Related]
34. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
36. Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis.
Du WX; Duan SF; Chen JJ; Huang JF; Yin LM; Tong PJ
J Cancer Res Ther; 2014 Nov; 10 Suppl():C140-3. PubMed ID: 25450272
[TBL] [Abstract][Full Text] [Related]
37. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
Ritzke C; Stieber P; Untch M; Nagel D; Eiermann W; Fateh-Moghadam A
Anticancer Res; 1998; 18(2B):1243-9. PubMed ID: 9615795
[TBL] [Abstract][Full Text] [Related]
38. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
39. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
40. Biochemical parameters of bone metabolism in bone metastases of solid tumors (review).
Meijer WG; van der Veer E; Willemse PH
Oncol Rep; 1998; 5(1):5-21. PubMed ID: 9458286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
